Table 1 The relationship between DDX27 expression and clinical pathology factors in 165 breast cancer patients
From: DEAD-box helicase 27 enhances stem cell-like properties with poor prognosis in breast cancer
Factors | Number (%) | DDX27 | χ2 | p-value | Crude OR (95% CI) | |
|---|---|---|---|---|---|---|
Low (%) | High (%) | |||||
Age | 0.253 | 0.6149a | ||||
< 60 | 127 (76.97) | 51 (30.91) | 76 (46.06) | Reference | ||
≥ 60 | 38 (23.03) | 17 (10.30) | 21 (12.73) | 0.6151b | 0.829 (0.399–1.722) | |
Tumor size | 12.053 | 0.0005a | ||||
< 3 | 95 (57.58) | 50 (30.30) | 45 (27.27) | Reference | ||
≥ 3 | 70 (42.42) | 18 (10.91) | 52 (31.52) | 0.0007b | 3.210 (1.642–6.276) | |
Lymph node status | 11.334 | 0.0008a | ||||
Negative | 109 (66.06) | 55 (32.73) | 54 (32.73) | Reference | ||
Positive | 56 (33.94) | 13 (7.88) | 43 (26.06) | 0.0010b | 3.369 (1.631–6.957) | |
ER | 3.137 | 0.0765a | ||||
Negative | 54 (32.73) | 17 (10.30) | 37 (22.42) | Reference | ||
Positive | 111 (67.27) | 51 (30.91) | 60 (36.36) | 0.0783b | 0.541 (0.272–1.072) | |
PR | 1.203 | 0.2726a | ||||
Negative | 54 (32.73) | 19 (11.52) | 35 (21.21) | Reference | ||
Positive | 111 (67.27) | 49 (29.70) | 62 (37.58) | 0.2737b | 0.687 (0.351–1.346) | |
HER2 | 0.232 | 0.6298a | ||||
Negative | 138 (83.64) | 58 (35.15) | 80 (48.48) | Reference | ||
Positive | 27 (16.36) | 10 (6.06) | 17 (10.30) | 0.6302b | 1.232 (0.526–2.887) | |
Ki-67 index (%) | 7.466 | 0.0063a | ||||
< 20 | 34 (20.61) | 21 (12.73) | 13 (7.88) | Reference | ||
≥ 20 | 131 (79.39) | 47 (28.48) | 84 (50.91) | 0.0076b | 2.887 (1.326–6.288) | |
Molecular subtype | 2.570 | 0.4628a | ||||
Luminal A | 23 (13.94) | 12 (7.27) | 11 (6.67) | Reference | ||
Luminal B | 81 (49.09) | 35 (21.21) | 46 (27.88) | 0.4470b | 1.434 (0.566–3.629) | |
HER2 | 27 (16.36) | 10 (6.06) | 17 (10.30) | 0.2845b | 1.855 (0.598–5.748) | |
TNBC | 34 (20.61) | 11 (6.67) | 23 (13.94) | 0.1377b | 2.281 (0.768–6.776) | |
Histological grade | 8.282 | 0.0040a | ||||
I–II | 127 (76.97) | 60 (36.36) | 67 (40.61) | Reference | ||
III | 38 (23.03) | 8 (4.85) | 30 (18.18) | 0.0054b | 3.358 (1.429–7.890) | |
TNM stage | 23.606 | < 0.0001a | ||||
I | 37 (22.42) | 28 (16.97) | 9 (16.97) | Reference | ||
II | 109 (66.06) | 35 (21.21) | 74 (44.85) | < 0.0001b | 6.489 (2.767–15.217) | |
III | 19 (11.52) | 5 (3.03) | 14 (8.48) | 0.0005b | 9.333 (2.647–32.915) | |